Download Poster (442.58 KB)

Publication
  • ASN •
  • 26 October, 2024 •
  • •

VALIANT: Phase 3 Trial of Pegcetacoplan for Patients With Native or Post-Transplant Recurrent C3G or Primary IC-MPGN

Carla M Nester, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Larry A Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole Van De Kar, Marina Vivarelli, Patrick D Walker, Dean Wallace, Daniel Zecher, Li Li, Zhongshen Wang, Luis López Lázaro, Johan Szamosi, Fadi Fakhouri

Available materials

Oral Presentation
Publication
  • ASN •
  • 24 October, 2024 •
  • •

Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 52-week patient evolution

Anuja Java, Andrew S Bomback, David Kavanagh, Giuseppe Remuzzi, Gere Sunder-Plassmann, John Kanellis, Erica Daina, Patrick D. Walker, Zhongshen Wang, Zurish Ahmad, Fadi Fakhouri

Available materials

Poster
Publication
  • ASN •
  • 23 October, 2024 •
  • •

Efficacy and safety of SEL-212 in patients with refractory gout and chronic kidney disease: A post hoc analysis from the two Phase 3 DISSOLVE studies

Puja Khanna, Richard Johnson, Rehan Azeem, Aletta Falk, Bhavisha Desai, Hugues Santin-Janin, Herbert Baraf, Alan Kivitz

Available materials

Poster
Publication
  • ESPN •
  • 17 October, 2025 •
  • •

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary ​ IC-MPGN: Phase 3 VALIANT study results

Christoph Licht, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Nayoa Fujita, Larry A Greenbaum, Antonio Mastrangelo, Nabil Melhem, Nicole CAJ Van de Kar, Marina Vivarelli, Dean Wallace, Virginia Taliadouros, Johan Szamosi, Katie Gordon, Zhongshen Wang, Carla M Nester

Publication
  • ESPN •
  • 16 October, 2025 •
  • •

Pegcetacoplan for paediatric patients with​ C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Nicole CAJ Van de Kar, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Larry A Greenbaum, Christoph Licht, Antonio Mastrangelo, Nabil Melhem, Nayoa Fujita, Dean Wallace, Marina Vivarelli, Zhongshen Wang, Dima Decker, Johan Szamosi, Lucía Quintana-Gallardo, Carla M Nester

Publication
  • IPTA •
  • 18 September, 2025 •
  • •

Pegcetacoplan for post-transplant patients with complement 3 glomerulopathy or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis: an analysis of the phase 2 NOBLE and phase 3 VALIANT trials

Andrew S Bomback, David Kavanagh, Daniel Zecher, Julien Zuber, Ondrej Vicklicky, Li Li, Luis López Lázaro, Fadi Fakhouri

Available materials

Poster
Publication
  • WTC •
  • 2 August, 2025 •
  • •

Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis

Andrew S Bomback, David Kavanagh, Daniel Zecher, Julien Zuber, Ondrej Vicklicky, Li Li, Luis López Lázaro, Fadi Fakhouri

Available materials

Oral Presentation
Sign up for alerts